Contact information
Research groups
Sarah Gooding
Oxford-Celgene Research Fellow
I joined the Vyas group in 2017 on an Oxford-Celgene Research Fellowship. Previously I studied undergraduate medicine in Cambridge, followed by Oxford for clinical training. My clinical haematology specialty training was also completed in Oxford. During this time I was a Wellcome Trust Clinical Research Fellow, studying for a DPhil in the Human Immunology Unit in the Weatherall Institute. This was supervised by Hal Drakesmith (HIU) and Claire Edwards of the Botnar Research Institute, and focused on the role of BMP signalling in the bone-lining tumour niche of the bone marrow cancer Multiple Myeloma.
My research on the Oxford-Celgene Fellowship concerns the tracking of myeloma in patient-donated samples at a single-cell level. By analysing mutational differences in clones and subclones of the tumour throughout disease progression, we aim to understand more about why it may respond but then relapse following different sequential therapies. In collaboration with the Opperman group at the Botnar Research Institute, we will integrate this approach with analysing changes in the composition of immune and other microenvironmental cell types, and their role in achieving disease remission.
Recent publications
-
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).
Journal article
Sharpley FA. et al, (2020), Br J Haematol
-
Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.
Journal article
Gooding S. et al, (2020), Blood
-
Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: Challenges and measurable outcomes.
Journal article
Djebbari F. et al, (2020), Eur J Haematol
-
Gremlin 1 - small protein, big impact: the multiorgan consequences of disrupted BMP antagonism†.
Journal article
Gooding S. and Leedham SJ., (2020), J Pathol
-
Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Journal article
Gooding S. et al, (2019), Nat Commun, 10